Table 1. Study and Patient Characteristics of Included Studies for Analysis.
| Parameter | CHANCE7 | FASTER29 | POINT8 | PRINCE28 | THALES11 |
|---|---|---|---|---|---|
| Study design | Parallel, double-blind, placebo-controlled RCT | Factorial, double-blind RCT | Parallel, double-blind, placebo-controlled RCT | Parallel, open-label RCT | Parallel, double-blind placebo-controlled RCT |
| Sample size of active/control arms | Clopidogrel and ASA: 2584; ASA: 2586 | Clopidogrel and ASA: 198; ASA: 194 | Clopidogrel and ASA: 2432; ASA: 2449 | Ticagrelor and ASA: 336; Clopidogrel and ASA: 339 | Ticagrelor and ASA: 5523; ASA: 5493 |
| Treatment window from symptom onset, h | 24 | 24 | 12 | 24 | 24 |
| NIHSS score, range | 0-3 | 0-3 | 0-3 | 0-3 | 0-5 |
| ABCD2 score, range | 4-7 | NA | 4-7 | 4-7 | 6-7 |
| DAPT treatment duration, d | 21 | 90 | 90 | 21 | 30 |
| Country of publication | China | Canada | US | China | US |
| Countries that attended the trial | China | Canada, US | Australia, Canada, Finland, France, Germany, Mexico, New Zealand, Spain, United Kingdom, US | China | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hong Kong, Hungary, India, Italy, Mexico, Peru, Poland, Romania, Russia, Saudi Arabia, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, Vietnam |
| Clopidogrel | |||||
| Loading dose, mg | 300 | 300 | 600 | 300 | NA |
| Maintenance dose, mg | 75 | 75 | 75 | 75 | NA |
| Maintenance duration, d | 2-90 | 2-90 | 2-90 | 2-90 | NA |
| Ticagrelor | |||||
| Loading dose, mg | NA | NA | NA | 180 | 180 |
| Maintenance dose, mg | NA | NA | NA | 90 | 90 |
| Maintenance duration, d | NA | NA | NA | 2-90 | 2-30 |
| ASA | |||||
| Loading dose, mg | 75-300 | 162 | 50-325 | 100-300 | 300-325 |
| Maintenance dose, mg | 75 | 81 | 50-325 | 100 | 75-100 |
| Maintenance duration, d | Clopidogrel and ASA: 2-21; ASA: 2-90 | Clopidogrel and ASA: 2-90; ASA: 2-90 | Clopidogrel and ASA: 2-90; ASA: 2-90 | Ticagrelor and ASA: 2-21; Clopidogrel and ASA: 2-21 | Ticagrelor and ASA: 2-30; ASA: 2-30 |
| Follow-up period, d | 90 | 90 | 90 (76-104) | 7-90 | 30-60 |
| Median age, y | Clopidogrel and ASA: 63; ASA: 62 | Clopidogrel and ASA mean age: with simvastatin, 67.1; without simvastatin, 68.9; ASA mean age: with simvastatin, 66.6; without simvastatin, 69.8 | Clopidogrel and ASA: 65 ASA: 65 | Ticagrelor and ASA: 62; clopidogrel and ASA: 61 | Ticagrelor and ASA mean age: 65.2; ASA mean age: 65.1 |
| Male, % | 66.2 | 52.8 | 55.1 | 73.2 | 61.7 |
| White, % | NA | 91.8 | 75.1 | NA | 53.8 |
Abbreviations: ASA, acetylsalicylic acid (aspirin); DAPT, dual antiplatelet therapy; NA, not applicable; NIHSS, National Institutes of Health Stroke Scale; RCT, randomized clinical trial.